DK2218461T3 - CD40-antistofformulering og fremgangsmåder - Google Patents

CD40-antistofformulering og fremgangsmåder Download PDF

Info

Publication number
DK2218461T3
DK2218461T3 DK10162787.5T DK10162787T DK2218461T3 DK 2218461 T3 DK2218461 T3 DK 2218461T3 DK 10162787 T DK10162787 T DK 10162787T DK 2218461 T3 DK2218461 T3 DK 2218461T3
Authority
DK
Denmark
Prior art keywords
antibody
ser
val
leu
thr
Prior art date
Application number
DK10162787.5T
Other languages
English (en)
Inventor
Vahe Bedian
John Daniel Cusmano
Ronald Paul Gladue
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34738672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2218461(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK2218461T3 publication Critical patent/DK2218461T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (3)

1. Flydende farmaceutisk formulering, som er egnet til parenteral indgivelse, omfattende et CD40-agonistantistof og en farmaceutisk acceptabel bærer, hvor formuleringen har en pH på 5,5, hvor antistoffet består af antistof 21.4.1, og hvor den farmaceutisk acceptable bærer omfatter natriumacetat, natriumchlorid og polysorbat 80.
2. Formulering ifølge krav 1, hvor koncentrationen af det nævnte CD40-antistof er i det mindste 5 mg/ml.
3. Formulering ifølge krav 2, hvor mængden af natriumacetat er 20 mM, mængden af natriumchlorid er 140 mM og mængden af polysorbat 80 er 0,2 mg/ml.
DK10162787.5T 2003-12-22 2004-12-09 CD40-antistofformulering og fremgangsmåder DK2218461T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53163903P 2003-12-22 2003-12-22
EP04801378A EP1706143A1 (en) 2003-12-22 2004-12-09 Cd40 antibody formulation and methods

Publications (1)

Publication Number Publication Date
DK2218461T3 true DK2218461T3 (da) 2016-05-17

Family

ID=34738672

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10162787.5T DK2218461T3 (da) 2003-12-22 2004-12-09 CD40-antistofformulering og fremgangsmåder

Country Status (20)

Country Link
US (4) US20050136055A1 (da)
EP (3) EP3081933A1 (da)
JP (3) JP2007515469A (da)
KR (2) KR100847944B1 (da)
CN (2) CN1897971A (da)
AU (1) AU2004308749B2 (da)
BR (1) BRPI0418029B8 (da)
CA (2) CA2704300A1 (da)
DK (1) DK2218461T3 (da)
ES (1) ES2580002T3 (da)
HU (1) HUE027717T2 (da)
IL (2) IL175540A (da)
NO (1) NO343797B1 (da)
NZ (2) NZ547162A (da)
PL (1) PL2218461T3 (da)
RU (1) RU2355421C2 (da)
SI (1) SI2218461T1 (da)
TW (1) TWI359671B (da)
WO (1) WO2005063289A1 (da)
ZA (1) ZA200603804B (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
MX2008007140A (es) * 2005-12-09 2009-03-04 Seattle Genetics Inc Metodos para utilizar agentes de union a cd40.
CN101479375B (zh) 2006-05-03 2016-03-30 科罗拉多州立大学董事会 Cd40激动剂抗体/1型干扰素协同佐剂组合、包含前述的结合物及其作为增强细胞免疫的治疗剂的用途
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
WO2008150494A1 (en) 2007-05-30 2008-12-11 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2010024676A1 (en) * 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a cd40 agonist to a tumor draining lymph node of a subject
US9561214B2 (en) * 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
MX339239B (es) 2011-04-29 2016-05-18 Apexigen Inc Anticuerpos anti-cd40 y metodos de uso.
KR20200075023A (ko) 2012-05-04 2020-06-25 화이자 인코포레이티드 전립선 관련된 항원 및 백신 기재 면역치료 요법
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
AU2013337903B2 (en) 2012-10-30 2018-08-16 Apexigen, Inc. Anti-CD40 antibodies and methods of use
US9856319B2 (en) 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
US10533054B2 (en) 2013-01-31 2020-01-14 Thomas Jefferson University Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system
DK3444271T3 (da) 2013-08-08 2022-01-10 Cytune Pharma Il-15- og il-15r-alfa-sushi-domænebaserede modulokiner
SG11201702598XA (en) 2014-10-29 2017-05-30 Seattle Genetics Inc Dosage and administration of non-fucosylated anti-cd40 antibodies
WO2017009843A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
EP3426271A4 (en) 2016-03-10 2019-10-16 Cold Genesys, Inc. METHODS OF TREATING SOLID OR LYMPHATIC TUMORS BY POLYTHERAPY
JP7148504B2 (ja) 2016-06-08 2022-10-05 ゼンコー，インコーポレイティド ＣＤ３２Ｂに交差結合した抗ＣＤ１９抗体を用いたＩｇＧ４関連疾患の治療
AU2017281830B2 (en) 2016-06-20 2023-04-06 Kymab Limited Anti-PD-L1 antibodies
WO2018088850A2 (ko) * 2016-11-11 2018-05-17 다이노나(주) Cd40에 특이적으로 결합하는 항체 및 그의 용도
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
KR102198998B1 (ko) * 2017-06-01 2021-01-07 서울대학교 산학협력단 신규한 항-ｃｄ40 항체 및 이의 용도
TW201902462A (zh) * 2017-06-02 2019-01-16 瑞士商赫孚孟拉羅股份公司 用於免疫促效劑之新穎投與途徑
EP3418302A1 (en) * 2017-06-19 2018-12-26 F. Hoffmann-La Roche AG Administration routes for immune agonists
CA3097007A1 (en) * 2018-04-20 2019-10-24 Lyvgen Biopharma Co., Ltd. Anti-cd40 antibodies and uses thereof
US20210251994A1 (en) 2018-06-15 2021-08-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
CN116178544A (zh) 2018-09-28 2023-05-30 礼进生物医药科技（上海）有限公司 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途
JP2022503961A (ja) * 2018-09-28 2022-01-12 リビジェン バイオファーマ カンパニー リミテッド 操作されたＦｃドメインを有する抗ＣＤ４０結合分子およびその治療用途
KR20210097750A (ko) * 2018-11-30 2021-08-09 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Cd40 항체 약학 조성물 및 이의 용도
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4106819A1 (en) 2020-02-21 2022-12-28 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
CN116234575A (zh) * 2020-06-04 2023-06-06 赛尔疫苗私人有限公司 激动剂抗cd40抗体
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
WO2022006327A1 (en) 2020-07-01 2022-01-06 Silverback Therapeutics, Inc. Anti-asgr1 antibody conjugates and uses thereof
AU2022246895A1 (en) 2021-03-31 2023-10-19 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
EP4363059A1 (en) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
JP2547556B2 (ja) * 1987-02-06 1996-10-23 株式会社 ミドリ十字 ｒ−グロブリンの液状製剤
SE8701004D0 (sv) 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
JPH03204821A (ja) * 1989-12-28 1991-09-06 Green Cross Corp:The モノクローナル抗体含有水溶液の加熱処理方法
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
AU5098493A (en) 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
NZ273504A (en) * 1993-10-01 1997-12-19 Immunex Corp Monoclonal antibodies (moabs) that specifically bind human cd40 molecules and cd40 ligand binding
DE69433820T2 (de) * 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0999853B1 (en) * 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
ES2557768T3 (es) * 1999-06-01 2016-01-28 Biogen Ma Inc. Un anticuerpo monoclonal bloqueante frente a VLA-1 y su uso para el tratamiento de trastornos inflamatorios
US6358670B1 (en) * 1999-12-28 2002-03-19 Electron Vision Corporation Enhancement of photoresist plasma etch resistance via electron beam surface cure
AU2228901A (en) * 1999-12-28 2001-07-09 Chugai Seiyaku Kabushiki Kaisha Stable antibody compositions and injection preparations
JP2003524644A (ja) 2000-02-01 2003-08-19 タノックス インコーポレイテッド Ｃｄ４０−結合性ａｐｃ−活性化分子
CN1981868A (zh) * 2000-03-31 2007-06-20 拜奥根Idec公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
US7063845B2 (en) * 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
AU2002211366A1 (en) * 2000-10-02 2002-04-15 Chiron Corporation Human anti-cd40 antibodies
ES2332402T5 (es) * 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
CA2454587C (en) * 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
JP5290489B2 (ja) * 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
AU2002357060A1 (en) * 2001-12-03 2003-06-17 Abgenix, Inc. Antibody categorization based on binding characteristics
US7115108B2 (en) 2002-04-02 2006-10-03 Becton, Dickinson And Company Method and device for intradermally delivering a substance
US20080009439A1 (en) * 2002-11-05 2008-01-10 Alsobrook John P Compositions and Methods of Use for a Fibroblast Growth Factor
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET

Also Published As

Publication number Publication date
EP3081933A1 (en) 2016-10-19
RU2006120950A (ru) 2008-01-27
NZ547162A (en) 2010-03-26
WO2005063289A1 (en) 2005-07-14
JP5634321B2 (ja) 2014-12-03
IL175540A0 (en) 2006-09-05
NO20063373L (no) 2006-09-21
KR100847944B1 (ko) 2008-07-22
BRPI0418029B8 (pt) 2021-05-25
TW200521142A (en) 2005-07-01
US20090311254A1 (en) 2009-12-17
IL201409A0 (en) 2010-05-31
US20120263732A1 (en) 2012-10-18
ES2580002T3 (es) 2016-08-18
CN1897971A (zh) 2007-01-17
EP1706143A1 (en) 2006-10-04
CA2704300A1 (en) 2005-07-14
AU2004308749B2 (en) 2010-10-28
KR20070012626A (ko) 2007-01-26
JP2014205692A (ja) 2014-10-30
SI2218461T1 (sl) 2016-08-31
ZA200603804B (en) 2007-09-26
PL2218461T3 (pl) 2016-09-30
KR20080023766A (ko) 2008-03-14
US20050136055A1 (en) 2005-06-23
CA2549652A1 (en) 2005-07-14
AU2004308749A1 (en) 2005-07-14
CN102552905A (zh) 2012-07-11
EP2218461B1 (en) 2016-04-20
NO343797B1 (no) 2019-06-11
BRPI0418029B1 (pt) 2018-12-26
JP2007515469A (ja) 2007-06-14
RU2355421C2 (ru) 2009-05-20
US20110104182A1 (en) 2011-05-05
HUE027717T2 (en) 2016-10-28
BRPI0418029A (pt) 2007-04-17
IL175540A (en) 2011-10-31
TWI359671B (en) 2012-03-11
JP2011184446A (ja) 2011-09-22
EP2218461A1 (en) 2010-08-18
CA2549652C (en) 2013-11-12
NZ583179A (en) 2011-06-30

Similar Documents

Publication Publication Date Title
DK2218461T3 (da) CD40-antistofformulering og fremgangsmåder
IL293244A (en) Agonist antibodies against icos and their uses
JP2017515815A (ja) レナリドミド及びポリペプチド構築物の組合せ、及びその使用
KR20220042067A (ko) Gm-csf 길항제를 사용한 암의 치료
US20220411512A1 (en) Combination treatment for cancer
JP2023512456A (ja) Ｉｌ－７タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法
CA3125962A1 (en) Antibodies specific to human nectin-2
CN112439060B (zh) Pd-l1免疫疗法的新用途
WO2023001118A1 (zh) 抗ox40抗体在联合用药中的应用
MXPA06006153A (en) Cd40 antibody formulation and methods
US20230014026A1 (en) Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint